Acelyrin, Inc. (NASDAQ:SLRN) CEO Mina Kim Sells 17,986 Shares

Acelyrin, Inc. (NASDAQ:SLRN) CEO Mina Kim sold 17,986 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the sale, the chief executive officer now directly owns 671,753 shares in the company, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Acelyrin Price Performance

NASDAQ:SLRN opened at $2.79 on Thursday. The business’s 50-day simple moving average is $2.26 and its 200-day simple moving average is $3.84. Acelyrin, Inc. has a fifty-two week low of $1.85 and a fifty-two week high of $8.59. The stock has a market capitalization of $279.91 million, a PE ratio of -1.13 and a beta of 1.25.

Acelyrin (NASDAQ:SLRN) last announced its earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.07. On average, research analysts expect that Acelyrin, Inc. will post -2.53 earnings per share for the current year.

Wall Street Analyst Weigh In

SLRN has been the topic of several research analyst reports. Citigroup decreased their price objective on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. Wells Fargo & Company dropped their price target on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, HC Wainwright decreased their target price on Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.60.

Institutional Investors Weigh In On Acelyrin

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in shares of Acelyrin by 30.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock valued at $8,144,000 after purchasing an additional 388,631 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Acelyrin by 81.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock worth $3,006,000 after buying an additional 273,604 shares in the last quarter. Point72 Asset Management L.P. raised its position in Acelyrin by 566.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 250,300 shares of the company’s stock valued at $1,234,000 after buying an additional 212,758 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in Acelyrin in the 3rd quarter valued at approximately $1,795,000. Finally, HighTower Advisors LLC acquired a new position in Acelyrin during the 3rd quarter worth approximately $50,000. 87.31% of the stock is owned by institutional investors.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.